<DOC>
	<DOCNO>NCT00003292</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness ifosfamide treat patient meningeal tumor recur remove surgically .</brief_summary>
	<brief_title>S9624 Ifosfamide Treating Patients With Meningeal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Estimate failure free survival , overall survival , response patient residual recurrent/progressive aggressive meningeal tumor ( malignant meningioma , hemangiopericytoma , primary nervous system sarcoma ) treat ifosfamide . - Evaluate toxicity ifosfamide patient population . OUTLINE : All patient receive ifosfamide IV continuously 72 hour day 1-3 21 day treatment course . Patients evaluated response/progression every 2 course . Patients stable disease receive 8 course therapy . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 35 patient accrue study .</detailed_description>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Hemangiopericytoma</mesh_term>
	<mesh_term>Fibrosarcoma</mesh_term>
	<mesh_term>Meningeal Neoplasms</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent unresectable : Malignant meningioma Intracranial hemangiopericytoma Primary central nervous system sarcoma , include : Fibrosarcoma Rhabdomyosarcoma Chondrosarcoma Leiomyosarcoma Measurable evaluable disease CT MRI scan Persistent disease follow biopsy incomplete resection OR Recurrent disease follow complete resection No benign meningioma No prior current systemic sarcoma PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Not specify Renal : Creatinine great 2.0 mg/dL Cardiovascular : No myocardial infarction within past 3 month No active angina No unstable heart rhythms No congestive heart failure Other : HIV negative No allergy study drug No serious concurrent medical psychiatric illness No uncontrolled peptic ulcer disease No prior malignancy within past 5 year except adequately treat : Basal squamous cell carcinoma skin Carcinoma situ cervix Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Recovered toxic effect prior therapy and/or postoperative complication Biologic therapy : Not specify Chemotherapy : No prior ifosfamide No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy ( except estrogen replacement therapy ) Corticosteroids allow dose stable decrease Radiotherapy : At least 4 week since prior radiotherapy Progressive disease follow radiation require No concurrent radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>